How Will VRTX Stock React To Its Upcoming Earnings? - Forbes
17 hours ago • Google News
Vertex Pharmaceuticals Inc (VRTX)
US$ 434.03-0.3%
Price Chart
Key Statistics
Market Cap
$ 118.67B
P/E Ratio
0.00
Revenue (TTM)
$ 11.1B
Volume
1.6M
52W High
$ 519.88
52W Low
$ 377.85
Dividend Yield
0.00%
Beta
0.41
Technicals
50-Day MA
455.0198
200-Day MA
463.6964
52 Week High
519.88
52 Week Low
377.85
About VRTX
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with.
Employees
6100
Headquarters
Boston, MA
CEO
Dr. Jeffrey Marc Leiden M.D., Ph.D.
Latest News
How To Trade Vertex Pharmaceuticals Stock Ahead of Its Upcoming Earnings? - Trefis
Yesterday • Google News
Environment, Social and Governance (ESG) Risk Ratings
Total ESG Risk Score
30.84
Percentile: 44
Environmental Risk Score
5.65
Percentile: 8
Social Risk Score
24.22
Percentile: 8
Governance Risk Score
12.46
Percentile: 8
Controversy Level
ESG data provided by Sustainalytics, Inc.
VRTX
Category Average
2Moderate Controversy Level
NoneSevere
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg